Investigate other factors
Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
The authors also suggest a second potential pathway independent of GLP-1 for some of the cardiovascular effects
Their expanding role beyond weight management and glycemic control presents new considerations for bone remodeling, perioperative risk reduction, and postoperative recovery in orthopedic surgery
TRPV1-null mice are protected from diet-induced obesity
4th Edition